First Berlin – NanoRepro AG Research Update (14/03/2018)

First Berlin Equity Research has published a research update on NanoRepro AG (ISIN: DE0006577109). Analyst Ellis Acklin discontinues coverage of NanoRepro including all forecasts and price target.

Abstract
Last December, NanoRepro announced an agreement with the dm drugstore chain to distribute four rapid diagnostic tests from its portfolio. The company also updated its outlook for 2018 and now sees sales approaching €2.5m (+40% Y/Y) with a break-even EBITDA. We discontinue coverage of NanoRepro including all forecasts and price target.